Snss stock offering
SNSS Stock - Sunesis Pharmaceuticals Inc SEC Filings Ticker: SNSS Sunesis Pharmaceuticals Inc is registered with the U.S. Security and Exchange Commission. This page includes all SEC filing details as well as a list of any documents (S-1, Prospecuts, Current Reports, 8-K, 10K, Annual Reports) registered by Sunesis Pharmaceuticals Inc. trading4living - StockTwits What I'm offering: Real -time daily analysis of equities I'm trading (as well as markets micro & macro) I let the charts & experience dictate setups; not news , analysts, or other outside factors. Through years of proficiency in chart/tape reading I am able to capture short term profits consistently. SNSS - Sunesis Pharmaceutic Stock Price - Barchart.com Sunesis Pharmaceutic (SNSS) Sunesis Pharmaceutic (SNSS) the real-time prices displayed may have minor discrepancies when comparing the information with other sites offering real-time data, or with brokerage firms. A measure of how much a stock or commodity has risen or fallen over a one-year period. Barchart takes this Alpha and weights Stock Offerings: Isle of Capri Casinos - TheStreet
Apr 02, 2020 · View detailed financial information, real-time news, videos, quotes and analysis on Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS). Explore commentary …
Jul 15, 2019 · Sunesis Pharmaceuticals, Inc. (SNSS) is trending up in the market in today’s trading session. The company, one that is focused on the biotech industry, is currently trading at $0.90 after heading up 5.87% so far today. Sunesis Pharmaceuticals, Inc. Prices $15.5 Million Offering SOUTH SAN FRANCISCO, CA--(Marketwire - October 01, 2010) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced today the pricing of an underwritten offering of approximately 44.1 million units, each consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a public offering price of $0.35 per unit, for gross proceeds of approximately $15.5 SNSS Stock - Sunesis Pharmaceuticals Inc SEC Filings Ticker: SNSS Sunesis Pharmaceuticals Inc is registered with the U.S. Security and Exchange Commission. This page includes all SEC filing details as well as a list of any documents (S-1, Prospecuts, Current Reports, 8-K, 10K, Annual Reports) registered by Sunesis Pharmaceuticals Inc. trading4living - StockTwits What I'm offering: Real -time daily analysis of equities I'm trading (as well as markets micro & macro) I let the charts & experience dictate setups; not news , analysts, or other outside factors. Through years of proficiency in chart/tape reading I am able to capture short term profits consistently.
SNSS Stock Price | Sunesis Pharmaceuticals Inc. Stock ...
Sunesis Pharmaceuticals (SNSS) Prices $20M Common ... Jan 18, 2019 · Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock … SNSS News Today (Sunesis Pharmaceuticals) | MarketBeat Options Traders Expect Huge Moves in Sunesis (SNSS) Stock finance.yahoo.com - June 17 at 7:29 PM Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting Sunesis Announces Proposed Public Offering of Common Stock ... Jul 10, 2019 · SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares
Jan 17, 2019 · SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock (“Series E Stock”).
Sunesis Pharmaceuticals Inc. - NASDAQ:SNSS - Stock Quote ... Apr 02, 2020 · View detailed financial information, real-time news, videos, quotes and analysis on Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS). Explore commentary … Sunesis Pharmaceuticals (SNSS) Plans Public Offering of ... Sunesis Pharmaceuticals (SNSS) Plans Public Offering of Common Stock and Preferred Stock SNSS - Sunesis Pharmaceuticals, Inc. Summary, Stock Quote ...
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock (“Series F Stock”). The public offering price of each share of common stock is $0.60 and the public offering price
The Company has granted the underwriters an option for 30 days to purchase up to an additional 900,000 shares of the Series E Preferred Stock to cover over-allotments, if any. The offering is subject to customary closing conditions and is expected to close on October 18, 2019. Secondary Offering Definition - Investopedia Jul 11, 2019 · A dilutive secondary offering usually results in some sort of drop in stock price due to the dilution of per-share earnings, but markets can have unexpected reactions to secondary offerings. SNSS Sunesis Pharmaceuticals, Inc. Stock Quote Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire +16.34% Jul-08-19 08:30AM Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update GlobeNewswire +6.15% Sunesis Pharmaceuticals Inc. - NASDAQ:SNSS - Stock Quote ... Apr 02, 2020 · View detailed financial information, real-time news, videos, quotes and analysis on Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS). Explore commentary …
Sunesis Announces Pricing of $25 Million Offering of ... The public offering price of each share of common stock is $0.60 and the public offering price of each share of Series F Stock, convertible into 1,000 shares of common stock, is $600. Sunesis expects to receive combined gross proceeds of approximately $25 million from these offerings, before deducting the underwriting discounts and other SNSS.O - Sunesis Pharmaceuticals, Inc. 適時開示 | Reuters july 10 (reuters) - sunesis pharmaceuticals inc